Home/Biosimilar Atlas/Aflibercept/Eiyzey / Vgenfli

Eiyzey / Vgenfli

Aflibercept biosimilar developed by Sam Chun Dang Pharm, development code SCD411. Reference product Eylea.

Brands by market: Eiyzey and Vgenfli (EU) · Commercial partner or holder: Polpharma (EU) · Company profile
FDANot listed
EMAAug 2025authorised
MHRALicenseddate not shown
PMDASep 2025approved
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 3 of 7 markets
Connections
AfliberceptmoleculeSam Chun Dang Pharmdeveloper3 of 7markets1trial behind it0other products, same developer10rival developers in its markets

About Eiyzey / Vgenfli

This aflibercept was developed by Sam Chun Dang of Korea. In Europe it is sold by Polpharma under two names, Eiyzey and Vgenfli, approved in August 2025. In Japan it was approved in September 2025 under Sam Chun Dang's own name. It has not been filed in the United States.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union · Eiyzey

European Medicines Agency and European CommissionApproved
Brand
Eiyzey
Holder or applicant
Zaklady Farmaceutyczne Polpharma S.A.
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006745
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
EMA

European Union · Vgenfli

European Medicines Agency and European CommissionApproved
Brand
Vgenfli
Holder or applicant
Zaklady Farmaceutyczne Polpharma S.A.
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006192
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA

United Kingdom · Vgenfli

Medicines and Healthcare products Regulatory AgencyApproved
Brand
Vgenfli
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
40 mg/mL vial and syringe
Source
S023 (MHRA Products) · checked Sep 2026
PMDA

Japan · Aflibercept BS SCD

Pharmaceuticals and Medical Devices Agency and MHLWApproved
Brand
Aflibercept BS SCD
Holder or applicant
SamChunDang Pharm
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Sep 2025
Indications as licensed
Wet AMD, RVO macular oedema, myopic CNV
Presentations
40 mg/mL solution and kit
Remarks
Aflibercept Biosimilar 3.
Source
S020 (PMDA) · checked Sep 2026
HC

Canada

Not listed by HC.

CDSCO

India

Not listed by CDSCO.

EDE

United Arab Emirates

Not listed by EDE.

Trials behind this product

Comparative trials on ClinicalTrials.gov matched to Eiyzey / Vgenfli by development code, brand or developer. Registry data, sponsor-entered.

CandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionRegistry record
SCD411Sam Chun Dang PharmEyleaPhase 3Comparative efficacyCompletedAug 2020Sep 2022NCT04480463

Other developers in the same markets

Where Eiyzey / Vgenfli holds an approval, these are the other aflibercept biosimilars approved in that market.

MarketRivalsDevelopers (product)
EMA8Alteogen (Eyluxvi), Alvotech (Afiveg / Mynzepli), Amgen (Pavblu), Biocon Biologics (Yesafili), Celltrion (Eydenzelt), Formycon (Ahzantive / Baiama), Samsung Bioepis (Opuviz), Sandoz (Enzeevu / Afqlir)
MHRA7Alvotech (Afiveg / Mynzepli), Amgen (Pavblu), Biocon Biologics (Yesafili), Celltrion (Eydenzelt), Formycon (Ahzantive / Baiama), Samsung Bioepis (Opuviz), Sandoz (Enzeevu / Afqlir)
PMDA3Celltrion (Eydenzelt), Fuji Pharma (Aflibercept BS NIT), Global Regulatory Partners (Aflibercept BS GRP)

Chronology

Sources

All aflibercept biosimilars

Planning aflibercept biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.